[go: up one dir, main page]

NL300047I1 - Farmaceutische samenstelling. - Google Patents

Farmaceutische samenstelling.

Info

Publication number
NL300047I1
NL300047I1 NL300047C NL300047C NL300047I1 NL 300047 I1 NL300047 I1 NL 300047I1 NL 300047 C NL300047 C NL 300047C NL 300047 C NL300047 C NL 300047C NL 300047 I1 NL300047 I1 NL 300047I1
Authority
NL
Netherlands
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
NL300047C
Other languages
English (en)
Original Assignee
Hermens Walter Adrianus Joseph
Merkus Franciscus Wilhelmus He
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hermens Walter Adrianus Joseph, Merkus Franciscus Wilhelmus He filed Critical Hermens Walter Adrianus Joseph
Publication of NL300047I1 publication Critical patent/NL300047I1/nl

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL300047C 1988-07-01 2001-07-04 Farmaceutische samenstelling. NL300047I1 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8801670A NL8801670A (nl) 1988-07-01 1988-07-01 Farmaceutisch preparaat.

Publications (1)

Publication Number Publication Date
NL300047I1 true NL300047I1 (nl) 2001-09-03

Family

ID=19852556

Family Applications (2)

Application Number Title Priority Date Filing Date
NL8801670A NL8801670A (nl) 1988-07-01 1988-07-01 Farmaceutisch preparaat.
NL300047C NL300047I1 (nl) 1988-07-01 2001-07-04 Farmaceutische samenstelling.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL8801670A NL8801670A (nl) 1988-07-01 1988-07-01 Farmaceutisch preparaat.

Country Status (4)

Country Link
US (1) US5089482A (nl)
EP (1) EP0349091B1 (nl)
DE (2) DE10199066I1 (nl)
NL (2) NL8801670A (nl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE117554T1 (de) * 1989-10-18 1995-02-15 Ueno Seiyaku Oyo Kenkyujo Kk Behandlung von männlichen, hormonabhängigen krankheiten mit cyclodextrinen und derivaten davon.
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
NL9001681A (nl) * 1990-07-24 1992-02-17 Rijksuniversiteit Transmucosale geneesmiddelpreparaten en transmucosale toediening.
US5883087A (en) * 1991-01-07 1999-03-16 Pherin Corporation Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
DE4207922A1 (de) * 1992-03-13 1993-09-23 Pharmatech Gmbh Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung
DE4214953C2 (de) * 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
DE4227569C1 (de) * 1992-08-20 1994-06-09 Inst Chemo Biosensorik Verfahren zum empfindlichen enzymatischen Nachweis von anorganischem Phosphat
BE1007402A5 (nl) * 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
NZ270077A (en) * 1993-12-14 1996-04-26 Lilly Co Eli Aqueous complexes of benzothiophenes and cyclodextrins
US6066627A (en) * 1994-08-04 2000-05-23 Pherin Corporation Steroids as neurochemical initiators of change in human blood levels of LH
US5668097A (en) * 1994-08-12 1997-09-16 The Procter & Gamble Company Uncomplexed cyclodextrin solutions for odor control on inanimate surfaces
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5679573A (en) * 1995-07-27 1997-10-21 Abbott Laboratories Stabilized aqueous steroid immunoassay standards with cyclodextrins
US20030174864A1 (en) * 1997-10-27 2003-09-18 Digital Biometrics, Inc. Gambling chip recognition system
US5942501A (en) * 1996-08-16 1999-08-24 Collaborative Laboratories, Inc. Cyclodextrin derivative complex
NZ330726A (en) * 1998-06-18 2000-10-27 Dec Res Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
FR2784584B1 (fr) * 1998-10-14 2002-09-20 Adir Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine
DE19848303A1 (de) * 1998-10-14 2000-04-20 Schering Ag Kombination aus Gestagenen und Zuckern
FR2791572A1 (fr) * 1999-03-31 2000-10-06 Adir Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
UY27088A1 (es) * 2000-12-20 2002-07-31 Schering Ag Composiciones de complejos de estrógeno-ciclodextrina
FR2827516B1 (fr) * 2001-07-19 2003-09-19 Servier Lab Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
WO2004012712A1 (en) * 2002-08-02 2004-02-12 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders, contraception, and hormone replacement
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US6960337B2 (en) * 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
US7029657B2 (en) * 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
JP2006522833A (ja) * 2003-04-11 2006-10-05 バー・ラボラトリーズ,インコーポレイテッド エストロゲンおよびプロゲスチンの投与法
US20050043343A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
ES2258694T3 (es) * 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
CA2550811C (en) * 2003-12-24 2012-05-01 Jane Hirsh Temperature-stable formulations, and methods of development thereof
US20060045850A1 (en) * 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
US20060183724A1 (en) * 2005-02-03 2006-08-17 Diliberti Charles E Compositions of unconjugated estrogens and methods for their use
ZA200902902B (en) 2006-10-04 2010-07-28 M & P Patent Aktinegesellschaf Controlled release delivery system for nasal application of neurotransmitters
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
AU2012318391A1 (en) * 2011-10-07 2014-05-15 Florida State University Research Foundation Prophylactic and post-acute use of progesterone to better outcomes associated with concussion
GB201200062D0 (en) 2012-01-04 2012-02-15 Innotesto Bvba Estradiol oromucosal liquid compositions
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE895769C (de) * 1951-08-26 1953-11-05 Knoll Ag Verfahren zur Herstellung von Einschlussverbindungen physiologisch wirksamer organischer Verbindungen
DE2839033A1 (de) * 1978-09-05 1980-03-13 Schering Ag 3-oxo-4-pregnen-20 alpha -carbonsaeure- derivate, ihre herstellung und verwendung
HU181703B (en) 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
US4383993A (en) * 1980-05-30 1983-05-17 University Of Kentucky Research Foundation Nasal dosage forms containing natural female sex hormones
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
JPS58113275A (ja) * 1981-12-28 1983-07-06 Nichiban Co Ltd 感圧性接着剤組成物
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
SE8305864D0 (sv) * 1983-10-25 1983-10-25 L E Medical Ogondroppar
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones

Also Published As

Publication number Publication date
NL8801670A (nl) 1990-02-01
EP0349091B1 (en) 1992-05-06
DE68901417D1 (de) 1992-06-11
DE10199066I1 (de) 2002-02-21
EP0349091A1 (en) 1990-01-03
US5089482A (en) 1992-02-18

Similar Documents

Publication Publication Date Title
NL300047I1 (nl) Farmaceutische samenstelling.
DE68907659D1 (de) Warmhaertende organosiloxanzusammensetzung.
FI901102A0 (fi) Farmaceutiska kompositioner.
FI922364A (fi) Farmaceutiska kompositioner.
DE68911473D1 (de) Arzneimittelformulierungen.
DE58902185D1 (de) Ampulle.
FI880530A (fi) Med vaermare foersett bilsaete.
FI895681A0 (fi) Farmaceutisk komposition foer systemisk transdermal tillfoersel.
NO882653D0 (no) Doseringsform.
NO884377D0 (no) Doserings-/blandesproeyte.
FI893643A (fi) Farmaceutiska kompositioner.
DE68916395D1 (de) Zusammensetzung.
IT8820386A0 (it) Composizioni farmaceutiche orosolubili contenti acetilcisteina.
DE68907177D1 (de) Dosierungsform.
FI880374A0 (fi) Skyddshuva eller -film med krympfoermaoga.
FI883673A0 (fi) Farmaceutiska kompositioner.
DE68906193D1 (de) Hypersphyxia verursachende zusammensetzung.
DK16489A (da) Immunstimulerende praeparat.
DE68903729D1 (de) Tertiaere thiolaethoxylat-zusammensetzung.
DE68907609D1 (de) Arzneimittelzusammensetzung.
FI892552A0 (fi) Benzoyl- och ketonperoxidkomposition.
FI895989A0 (fi) Triazinoligomerestrar- och amider med en tetrametylpiperidylgrupp i aendstaellning.
FI890922A0 (fi) Oljekanna med vaeggbehaollare.
DE68916142D1 (de) Zusammensetzung.
DE68909455D1 (de) Polyaethylen-zusammensetzung.